Steps to Translate Preconditioning from Basic Research to the Clinic

Frances Bahjat, Raffaella Gesuete, Mary Stenzel-Poore

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Efforts to treat cardiovascular and cerebrovascular diseases often focus on the mitigation of ischemia-reperfusion (I/R) injury. Many treatments or "preconditioners" are known to provide substantial protection against I/R injury when administered prior to the event. Brief periods of ischemia itself have been validated as a means to achieve neuroprotection in many experimental disease settings, in multiple organ systems, and in multiple species suggesting a common pathway leading to tolerance. In addition, pharmacological agents that act as potent preconditioners have been described. Experimental induction of neuroprotection using these various preconditioning paradigms has provided a unique window into the brain's endogenous protective mechanisms. Moreover, preconditioning agents themselves hold significant promise as clinical-stage therapies for prevention of I/R injury. The aim of this article is to explore several key steps involved in the preclinical validation of preconditioning agents prior to the conduct of clinical studies in humans. Drug development is difficult, expensive, and relies on multifactorial analysis of data from diverse disciplines. Importantly, there is no single path for the preclinical development of a novel therapeutic and no proven strategy to ensure success in clinical translation. Rather, the conduct of a diverse array of robust preclinical studies reduces the risk of clinical failure by varying degrees depending upon the relevance of preclinical models and drug pharmacology to humans. A strong sense of urgency and high tolerance of failure are often required to achieve success in the development of novel treatment paradigms for complex human conditions.

Original languageEnglish (US)
Pages (from-to)89-103
Number of pages15
JournalTranslational Stroke Research
Volume4
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Reperfusion Injury
Research
Pharmacology
Cerebrovascular Disorders
Pharmaceutical Preparations
Cardiovascular Diseases
Ischemia
Brain
Therapeutics
Neuroprotection

Keywords

  • Animal models of stroke
  • Brain injury
  • Cardiovascular disease
  • Cerebral ischemia
  • Ischemia
  • Ischemic brain injury
  • MCAO
  • Mouse
  • Nonhuman primate
  • Occlusion
  • Preconditioning
  • Repercussion
  • Stroke
  • Therapeutic
  • Toll-like receptors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Steps to Translate Preconditioning from Basic Research to the Clinic. / Bahjat, Frances; Gesuete, Raffaella; Stenzel-Poore, Mary.

In: Translational Stroke Research, Vol. 4, No. 1, 2013, p. 89-103.

Research output: Contribution to journalArticle

Bahjat, Frances ; Gesuete, Raffaella ; Stenzel-Poore, Mary. / Steps to Translate Preconditioning from Basic Research to the Clinic. In: Translational Stroke Research. 2013 ; Vol. 4, No. 1. pp. 89-103.
@article{1f1dc6ac57024f019f15383b3a3a555a,
title = "Steps to Translate Preconditioning from Basic Research to the Clinic",
abstract = "Efforts to treat cardiovascular and cerebrovascular diseases often focus on the mitigation of ischemia-reperfusion (I/R) injury. Many treatments or {"}preconditioners{"} are known to provide substantial protection against I/R injury when administered prior to the event. Brief periods of ischemia itself have been validated as a means to achieve neuroprotection in many experimental disease settings, in multiple organ systems, and in multiple species suggesting a common pathway leading to tolerance. In addition, pharmacological agents that act as potent preconditioners have been described. Experimental induction of neuroprotection using these various preconditioning paradigms has provided a unique window into the brain's endogenous protective mechanisms. Moreover, preconditioning agents themselves hold significant promise as clinical-stage therapies for prevention of I/R injury. The aim of this article is to explore several key steps involved in the preclinical validation of preconditioning agents prior to the conduct of clinical studies in humans. Drug development is difficult, expensive, and relies on multifactorial analysis of data from diverse disciplines. Importantly, there is no single path for the preclinical development of a novel therapeutic and no proven strategy to ensure success in clinical translation. Rather, the conduct of a diverse array of robust preclinical studies reduces the risk of clinical failure by varying degrees depending upon the relevance of preclinical models and drug pharmacology to humans. A strong sense of urgency and high tolerance of failure are often required to achieve success in the development of novel treatment paradigms for complex human conditions.",
keywords = "Animal models of stroke, Brain injury, Cardiovascular disease, Cerebral ischemia, Ischemia, Ischemic brain injury, MCAO, Mouse, Nonhuman primate, Occlusion, Preconditioning, Repercussion, Stroke, Therapeutic, Toll-like receptors",
author = "Frances Bahjat and Raffaella Gesuete and Mary Stenzel-Poore",
year = "2013",
doi = "10.1007/s12975-012-0223-4",
language = "English (US)",
volume = "4",
pages = "89--103",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "1",

}

TY - JOUR

T1 - Steps to Translate Preconditioning from Basic Research to the Clinic

AU - Bahjat, Frances

AU - Gesuete, Raffaella

AU - Stenzel-Poore, Mary

PY - 2013

Y1 - 2013

N2 - Efforts to treat cardiovascular and cerebrovascular diseases often focus on the mitigation of ischemia-reperfusion (I/R) injury. Many treatments or "preconditioners" are known to provide substantial protection against I/R injury when administered prior to the event. Brief periods of ischemia itself have been validated as a means to achieve neuroprotection in many experimental disease settings, in multiple organ systems, and in multiple species suggesting a common pathway leading to tolerance. In addition, pharmacological agents that act as potent preconditioners have been described. Experimental induction of neuroprotection using these various preconditioning paradigms has provided a unique window into the brain's endogenous protective mechanisms. Moreover, preconditioning agents themselves hold significant promise as clinical-stage therapies for prevention of I/R injury. The aim of this article is to explore several key steps involved in the preclinical validation of preconditioning agents prior to the conduct of clinical studies in humans. Drug development is difficult, expensive, and relies on multifactorial analysis of data from diverse disciplines. Importantly, there is no single path for the preclinical development of a novel therapeutic and no proven strategy to ensure success in clinical translation. Rather, the conduct of a diverse array of robust preclinical studies reduces the risk of clinical failure by varying degrees depending upon the relevance of preclinical models and drug pharmacology to humans. A strong sense of urgency and high tolerance of failure are often required to achieve success in the development of novel treatment paradigms for complex human conditions.

AB - Efforts to treat cardiovascular and cerebrovascular diseases often focus on the mitigation of ischemia-reperfusion (I/R) injury. Many treatments or "preconditioners" are known to provide substantial protection against I/R injury when administered prior to the event. Brief periods of ischemia itself have been validated as a means to achieve neuroprotection in many experimental disease settings, in multiple organ systems, and in multiple species suggesting a common pathway leading to tolerance. In addition, pharmacological agents that act as potent preconditioners have been described. Experimental induction of neuroprotection using these various preconditioning paradigms has provided a unique window into the brain's endogenous protective mechanisms. Moreover, preconditioning agents themselves hold significant promise as clinical-stage therapies for prevention of I/R injury. The aim of this article is to explore several key steps involved in the preclinical validation of preconditioning agents prior to the conduct of clinical studies in humans. Drug development is difficult, expensive, and relies on multifactorial analysis of data from diverse disciplines. Importantly, there is no single path for the preclinical development of a novel therapeutic and no proven strategy to ensure success in clinical translation. Rather, the conduct of a diverse array of robust preclinical studies reduces the risk of clinical failure by varying degrees depending upon the relevance of preclinical models and drug pharmacology to humans. A strong sense of urgency and high tolerance of failure are often required to achieve success in the development of novel treatment paradigms for complex human conditions.

KW - Animal models of stroke

KW - Brain injury

KW - Cardiovascular disease

KW - Cerebral ischemia

KW - Ischemia

KW - Ischemic brain injury

KW - MCAO

KW - Mouse

KW - Nonhuman primate

KW - Occlusion

KW - Preconditioning

KW - Repercussion

KW - Stroke

KW - Therapeutic

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=84872656081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872656081&partnerID=8YFLogxK

U2 - 10.1007/s12975-012-0223-4

DO - 10.1007/s12975-012-0223-4

M3 - Article

VL - 4

SP - 89

EP - 103

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 1

ER -